How PeptideGuide rates research peptide vendors — the 5-axis weighted methodology
PeptideGuide evaluates every research peptide vendor on a 5-axis weighted methodology that produces the composite score (0-10) used in regional leaderboards and Editor's Choice designations. This article explains the axes, their weights, the rubrics that translate vendor attributes into axis scores, and the limitations of the methodology. Readers who want to know "why is Particle Peptides ranked above SwissChems" or "how did UAE Peptide Lab earn GCC Editor's Choice" find their answer here. The methodology is intentionally transparent — the rubrics are publishable so independent observers can verify scoring decisions.
The 5 axes and their weights: **Testing (30%)** — depth of Certificate-of-Analysis coverage. **Purity (20%)** — stated typical purity corroborated by lab reports. **EU-Friendliness (20%) / Regional-Friendliness** — warehouse location, payment infrastructure, language coverage, VAT/tax compliance, delivery time. **Value (15%)** — price versus evidence; cheap with no CoA is not value. **Trust (15%)** — time in market, review volume and authenticity, incident history. The composite score is a weighted sum of axis scores: `composite = 0.30 × testing + 0.20 × purity + 0.15 × regional + 0.15 × value + 0.20 × trust`.
Why testing is the heaviest weight (30%): research peptide quality cannot be verified by reputation alone. A vendor with 99.9% claimed purity and no Certificate-of-Analysis is operationally equivalent to a vendor making no claim at all — the buyer has no verification mechanism. Independent blind multi-lab CoA testing (where the vendor sends batches to a third-party lab without disclosing identity) is the gold-standard verification. PeptideGuide weights testing heaviest because it is the only axis where buyer self-verification is impossible without lab access.
Testing rubric (out of 10): **10** — 7-parameter independent blind multi-lab CoA covering HPLC (purity), LC-MS (identity), FTIR (structural confirmation), CLND (peptide content), LAL (endotoxin), TAMC/TYMC (microbial counts), heavy metals. Only Particle Peptides currently meets this rubric in the EU segment. **8** — HPLC + LC-MS + one additional method, independently issued. Research Peptides Europe (FTIR-inclusive 6-method) and PeptidesDirect (Janoshik Analytical-issued HPLC+LC-MS) sit here. **6** — HPLC + LC-MS independently issued. **5** — In-house-only CoA. Most US-domestic mid-tier vendors (Core Peptides multi-lab structure earns higher; SwissChems, Umbrella Labs, Pharma Lab Global sit in the 6-7 range). **3** — No CoA published per batch. Disqualifying for any Editor's Choice consideration.
Purity rubric (out of 10): **10** — ≥99.5% with independent CLND peptide content verification. **9** — 99.0-99.4% with HPLC + LC-MS. Most credible mid-tier vendors land here. **7** — 98.0-98.9%. **5** — 97.0-97.9%. Purity claims without sourcing cap at 7 — claims over 99% without independent CLND verification are treated with appropriate skepticism. The axis rewards verifiable purity, not marketing copy.
EU-Friendliness / Regional-Friendliness rubric (out of 10): the axis name is "EU-Friendliness" for the EU site but evaluates regional-friendliness for each regional leaderboard (AU-friendliness for AU, JP-friendliness for JP, etc.). **10** — Regional warehouse + regional payment infrastructure (SEPA for EU, E-transfer for CA, regional bank transfer elsewhere) + 5+ language support + regional VAT/tax compliance. **8** — Regional warehouse + card/regional payment + regional VAT. **6** — Non-regional with fast, duty-paid regional delivery. **4** — Non-regional with customs risk. This axis structurally favors regional-domestic vendors over international shippers — which is editorially intentional, since regional logistics affect total cost of ownership.
Value rubric (out of 10): **10** — Lowest segment price with credible independent CoA. **8** — Competitive price with full CoA. **6** — Typical segment price. **4** — Premium price without proportional testing depth. The axis explicitly rejects "cheap with no CoA" as value — the testing-evidence-to-price ratio is the calculation, not raw price. A vendor charging €50 for 7-parameter CoA-verified product earns a higher value score than a vendor charging €20 for unverified product.
Trust rubric (out of 10): **10** — 5+ years operating + 100+ authentic reviews + no incidents. **8** — 3+ years + 50+ reviews + no incidents. **5** — New brand with limited review history. **3** — Any open incident (delayed deliveries, customer-service complaints in volume, regulatory inquiries). **2** — Active critical incident (GDPR violation, fraud allegation, non-delivery pattern). Trust caps at 3 for any vendor with an open incident regardless of other axes — this is the editorial safety mechanism that prevents otherwise-strong vendors from ranking above credibility-compromised vendors.
Composite-score interpretation: **9.0-10.0** Editor's Choice tier. **8.0-8.9** mid-tier credible alternative. **7.0-7.9** acceptable for specific buyer profiles (typically value-seekers willing to accept testing-depth or regional-friendliness trade-offs). **6.0-6.9** weak — included in catalog for buyers with specific narrow requirements. **<6.0** flagged with explicit warnings or excluded from regional leaderboards entirely. The Editor's Choice designation goes to the highest-scoring vendor per region; ties are broken by the trust axis.
The personalized finder weighting: beyond the static methodology, the on-site finder applies multipliers to specific axes based on buyer-priority answers. "Strict testing & CoA depth" multiplies testing×1.6, purity×1.3, trust×1.2. "Lowest price, credible CoA" multiplies value×1.6, testing×0.9. "Institutional procurement" multiplies regional-friendliness×1.4, trust×1.4, testing×1.1. "Speed" multiplies regional-friendliness×1.5, value×1.1. The finder ranks vendors per individual buyer priority profile, generating a personalized recommendation distinct from the static composite ranking.
Methodology limitations and honest disclaimers: (1) Testing scores reflect publicly disclosed CoA structure — vendors that test more deeply than they publish are scored on disclosure not actual testing. (2) Trust scores require multi-year operating history; new vendors (Founded <2 years) are penalized even if quality is high. (3) Regional-friendliness scores are buyer-side-tax-included; a vendor with no warehouse but excellent regional shipping can score below a regional warehouse that ships slower. (4) Value scores are sensitive to segment pricing trends; a vendor that maintains its prices while the segment drops will see value-score erosion over time. (5) Affiliate-program economics are NOT scored — methodology evaluates buyer-side quality, not seller-side affiliate appeal. PeptideGuide discloses every affiliate relationship at /disclosures; the methodology weighting is unaffected by affiliate commission rates.
How methodology updates work: PeptideGuide reviews vendor scores quarterly. New CoA disclosures, regulatory inquiries, new operating-history milestones, and pricing-tier shifts can move scores up or down. Significant methodology changes (axis weight adjustments, rubric refinements) are documented publicly with the rationale. The current methodology was last refined in early 2026; the next scheduled review is mid-2026.
✓Pros
- Five weighted axes — Testing (30%), Purity (20%), Regional-Friendliness (20%), Value (15%), Trust (15%)
- Publishable rubrics — every score level (1-10) has a published rubric
- Personalized finder with axis multipliers per buyer-priority answer
- Quarterly methodology review with public documentation of changes
- Affiliate commissions explicitly excluded from scoring
- Trust-axis safety mechanism caps at 3 for any open incident
×Cons
- Testing scored on disclosure not actual testing — vendors testing deeper than they publish are penalized
- New vendors (<2 years operating) structurally penalized by trust axis
- Methodology does not evaluate vendor manufacturing capability directly (no on-site audits)
- Regional-friendliness axis structurally favors regional-domestic over international
- Pricing-trend sensitive — vendor scores can erode without action if segment pricing shifts
Why does testing get the heaviest weight (30%)?
Research peptide quality is one of the few product categories where buyer self-verification is structurally impossible without lab access. A vendor with 99.9% claimed purity and no CoA is operationally equivalent to a vendor making no claim. Independent blind multi-lab CoA testing (third-party lab tests batches without knowing vendor identity) is the only way to verify quality claims. PeptideGuide weights testing heaviest because it is the only axis where buyer self-verification is impossible.
Do affiliate commissions affect vendor scoring?
No — methodology scoring is independent of affiliate relationships. PeptideGuide discloses every affiliate relationship at /disclosures, and the 5-axis methodology evaluates buyer-side quality (testing depth, purity verification, regional shipping logistics, value-per-CoA-evidence, trust history). The methodology does NOT weight affiliate commission rates. Editor's Choice picks are made on composite-score grounds; some Editor's Choice picks (PeptidesDirect) do not even have affiliate programs.
Why does Particle Peptides hold EU Editor's Choice at 9.2 when other vendors test well?
Particle Peptides is the only documented EU vendor at the 10/10 testing rubric — 7-parameter independent blind multi-lab CoA covering HPLC, LC-MS, FTIR, CLND, LAL, TAMC/TYMC, heavy metals. Research Peptides Europe (8/10, FTIR-inclusive 6-method) and PeptidesDirect (8/10, Janoshik-issued HPLC+LC-MS) sit one tier below. Combined with Particle Peptides' 12-year operating history (full 10/10 on trust axis) and broad EU warehouse coverage (10/10 EU-friendliness), the composite score is decisive. See [Particle Peptides full review](/research/particle-peptides-full-review-2026).
Can I trust the rankings if PeptideGuide takes affiliate commissions?
Methodology transparency is the answer. Every axis has a published rubric; every vendor score is defensible against the rubric. Independent observers can verify scoring decisions by cross-referencing vendor public disclosures against the published rubric. PeptideGuide additionally publishes the affiliate-relationship disclosures at /disclosures, identifies non-affiliate-program vendors in the catalog (PeptidesDirect has no affiliate program but ranks in EU leaderboard), and includes vendors with active flagged incidents in the catalog with explicit warnings rather than removing them. The structural design separates editorial methodology from affiliate revenue.
How often does the methodology change?
Quarterly. Vendor scores are reviewed quarterly for new CoA disclosures, regulatory inquiries, operating-history milestones, and pricing-tier shifts. Methodology axis weights and rubrics are reviewed annually with publicly documented rationale for any significant changes. The current methodology was last refined in early 2026; the next scheduled methodology review is mid-2026.
Does the finder produce different rankings than the static leaderboard?
Yes — intentionally. The static leaderboard reflects the weighted-composite score across all 5 axes per the standard weighting (Testing 30%, Purity 20%, Regional-Friendliness 20%, Value 15%, Trust 15%). The finder applies buyer-priority-based axis multipliers — a buyer prioritizing "Lowest price, credible CoA" sees the value axis weighted 1.6x and testing 0.9x, producing a different ranking that favors value-tier vendors. The finder is the personalization layer; the static leaderboard is the editorial recommendation for the typical buyer.
What happens to vendors with active incidents?
Trust-axis caps at 3 for any open incident regardless of other axes. Active critical incidents (GDPR violations, fraud allegations, documented non-delivery patterns) cap trust at 2. This structural safety mechanism prevents otherwise-strong vendors with credibility-compromising incidents from ranking above smaller-but-clean vendors. Vendors with active warnings are listed in the catalog with explicit warning text on their entries — buyers see the warning before clicking through.
More from this region.
Other articles covering this region's vendors, regulatory framework, and research peptides.